Lipiduce 160 Special Precautions

Concomitant therapy with HMG-CoA reductase inhibitors (eg. Lovastatin, Pravastatin, Simvastatin), or Fenofibric acid derivatives (eg. Gemfibrozil) should be avoided, if use is warranted administer cautiously.
Concomitant therapy with anticoagulants; exercise caution.
Cholelithiasis.
Diabetic patients; increased risk of myopathies including rhabdomyolysis.
Elderly patients; increased risk of myopathies including rhabdomyolysis.
Hypothyroidism; increased risk of myopathies including rhabdomyolysis.
Hypersensitivity reactions have occurred including skin rashes requiring hospitalization and Stevens-Johnson syndrome.
Myopathies may occur; discontinuation of therapy may be warranted.
Pancreatitis.
Renal dysfunction; increased risk of myopathies including rhabdomyolysis.
Serum transaminases (AST and ALT) increases of more than 3 times the upper limit of normal have been reported: monitoring is recommended, discontinuation of therapy may be warranted.